Glenmark’s consolidated revenue increases by 15.92 per cent in Q3 FY 13-14
Net profit for the third quarter was Rs 2162.36 million as compared to Rs 2129.17 million for the previous corresponding quarter
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Biocon achieves 16 per cent growth in Q3 2013-14
The company's Malaysia facility is on track for commissioning in FY15
SPARC gets DCGI nod for breast cancer injection paclitaxel
As a part of the arrangement, SPARC is eligible for milestone and royalty income
US FDA bans drug manufactured from Ranbaxy’s Toansa facility
Toansa facility is now subject to certain terms of a consent decree of permanent injunction entered against Ranbaxy in January…
Wipro cited as leader in global research and advisory firm report
The report evaluates worldwide life science manufacturing and supply chain ITO services providers across 24 criteria
Unichem Laboratories obtains ANDA approval from US FDA for metronidazole tablets
The product will be commercialised from Unichem’s Ghaziabad plant
Aurobindo Pharma gets US FDA approval for repaglinide tabs
Repaglinide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus
Jubilant Life Sciences revamps official website
The company has been recognisd as the ‘Partner of Choice’ to leading life sciences companies worldwide
Biocon inks pact with Advaxis for development of novel cervical cancer immunotherapy
Advaxis will manufacture and supply ADXS-HPV to Biocon
Almac publishes breast cancer chemotherapy response assay in JNCI
The assay was developed by Almac in collaboration with Queens University, Belfast and the Mayo Clinic, Rochester, US